Search Results - "Stephens, R. W."

Plasma urokinase receptor levels in patients with colorectal cancer : Relationship to prognosis by STEPHENS, R. W, NIELSEN, H. J, CHRISTENSEN, I. J, THORLACIUS-USSING, O, SØRENSEN, S, DANØ, K, BRÜNNER, N

“…The proteolytic enzyme plasmin, which is generated from the precursor plasminogen by the action of urokinase plasminogen activator, is thought to play a role…”
Get full text

Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer by HOLTEN-ANDERSEN, M. N, MURPHY, G, NIELSEN, H. J, PEDERSEN, A. N, CHRISTENSEN, I. J, HØYER-HANSEN, G, BRÜNNER, N, STEPHENS, R. W

“…A kinetic enzyme-linked immunosorbent assay (ELISA) for plasma tissue inhibitor of metalloproteinase (TIMP)-1 was developed in order to examine the potential…”
Get full text

Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis by Slot, Ole, Brünner, Nils, Locht, Henning, Oxholm, Peter, Stephens, Ross W

“…OBJECTIVE Urokinase type plasminogen activator (uPA) catalyses the formation of the proteolytic enzyme plasmin, which is involved in matrix degradation in the…”
Get full text

Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer by KOS, J, NIELSEN, H.-J, KRASOVEC, M, CHRISTENSEN, I. J, CIMERMAN, N, STEPHENS, R. W, BRÜNNER, N

“…The level of cathepsin B (Cat B) was determined in sera obtained preoperatively from 325 patients with colorectal cancer using an ELISA. Control sera from 90…”
Get full text

Soluble Urokinase Plasminogen Activator Receptor in Preoperatively Obtained Plasma from Patients with Gynecological Cancer or Benign Gynecological Diseases by Riisbro, R., Stephens, R.W., Brünner, N., Christensen, I.J., Nielsen, H.J., Heilmann, L., von Tempelhoff, G.-F.

“…Objective. The present study was planned to measure preoperative levels of soluble urokinase plasminogen activator receptor (suPAR) in plasma from patients…”
Get full text

Lactational competence and involution of the mouse mammary gland require plasminogen by Lund, Leif R., Bjørn, Signe F., Sternlicht, Mark D., Nielsen, Boye S., Solberg, Helene, Usher, Pernille A., Østerby, Ruth, Christensen, Ib J., Stephens, Ross W., Bugge, Thomas H., Danø, Keld, Werb, Zena

“…Urokinase-type plasminogen activator expression is induced in the mouse mammary gland during development and post-lactational involution. We now show that…”
Get full text

ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients by Stephens, Ross W, Pedersen, Anders N, Nielsen, Hans Jorgen, Hamers, Maria J. A. G, Hoyer-Hansen, Gunilla, Ronne, Ebbe, Dybkjær, Esben, Dano, Keld, Brunner, Nils

“…Measurement of urokinase receptor (uPAR) in tumor extracts has prognostic value, but assay of the soluble uPAR (suPAR) in peripheral blood may offer wider…”
Get full text

Activation of Pro-Urokinase and Plasminogen on Human Sarcoma Cells: A Proteolytic System with Surface-Bound Reactants by Stephens, Ross W., Pöllänen, Jari, Tapiovaara, Hannele, Leung, Kin-Chuen, Sim, Pheng-Siew, Salonen, Eeva-Marjatta, Rønne, Ebbe, Behrendt, Niels, Danø, Keld, Vaheri, Antti

“…Human HT-1080 fibrosarcoma cells produce urokinase-type plasminogen activator (u-PA) and type 1 plasminogen activator inhibitor (PAI-1). We found that after…”
Get full text

Soluble urokinase receptor released from human carcinoma cells: A plasma parameter for xenograft tumour studies by HOLST-HANSEN, C, HAMERS, M. J. A. G, JOHANNESSEN, B. E, BRÜNNER, N, STEPHENS, R. W

“…The urokinase plasminogen activator receptor (uPAR) plays a critical role in urokinase-mediated plasminogen activation and thereby in the process leading to…”
Get full text

Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance by Sier, C F, Sidenius, N, Mariani, A, Aletti, G, Agape, V, Ferrari, A, Casetta, G, Stephens, R W, Brünner, N, Blasi, F

“…High levels of urokinase-type plasminogen activator receptor (uPAR) are expressed in various types of cancer. Recent studies showed that cancer patients may…”
Get more information

Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy by Mustjoki, S, Alitalo, R, Stephens, R W, Vaheri, A

“…Plasminogen activation in leukemia has been less well characterized than in other malignancies. However, the increased tendency to bleeding and tissue…”
Get more information

Directed plasminogen activation at the surface of normal and malignant cells by Pöllänen, J, Stephens, R W, Vaheri, A

Get more information

Distribution and lateral mobility of the urokinase-receptor complex at the cell surface by Myohanen, HT, Stephens, RW, Hedman, K, Tapiovaara, H, Ronne, E, Hoyer-Hansen, G, Dano, K, Vaheri, A

“…Pro-urokinase (pro-uPA) and activated uPA are confined to focal adhesions and cell-cell contacts. We studied the distribution of the uPA receptor (uPAR) on…”
Get full text

Protamine sulphate inhibits platelet membrane glycoprotein Ib-von Willebrand factor activity by Barstad, R M, Stephens, R W, Hamers, M J, Sakariassen, K S

“…Platelet adhesion to the injured vessel wall is essential in haemostasis and thrombosis. This process involves the interaction of the platelet glycoprotein Ib…”
Get more information

Quantification of Tissue Inhibitor of Metalloproteinases 2 in Plasma from Healthy Donors and Cancer Patients by Larsen, M. B., Stephens, R. W., Brünner, N., Nielsen, H. J., Engelholm, L. H., Christensen, I. J., Stetler‐Stevenson, W. G., Høyer‐Hansen, G.

“…Tissue inhibitor of metalloproteinases (TIMP)‐2 is a highly conserved molecule, which binds both active and latent matrix metalloproteinase (MMP)‐2. TIMP‐2 is…”
Get full text

Loss of ELISA specificity due to biotinylation of monoclonal antibodies by Høyer-Hansen, Gunilla, Hamers, Maria J.A.G, Pedersen, Anders N, Nielsen, Hans Jørgen, Brünner, Nils, Danø, Keld, Stephens, Ross W

“…A significant degree of nonspecificity was found in ELISA determinations of soluble urokinase receptor (suPAR) in human blood plasma when biotinylated…”
Get full text

A new immunocapture assay for Escherichia coli beta-galactosidase for in vivo studies of lacZ-transduced tumor cells by Holst-Hansen, C, Brünner, N, Johannessen, B E, Felding, J, Stephens, R W

Get more information

Retinoic acid reduces induction of monocyte tissue factor and tissue factor/factor VIIa-dependent arterial thrombus formation by BARSTAD, R. M, HAMERS, M. J. A. G, STEPHENS, R. W, SAKARIASSEN, K. S

“…Agents that downregulate the induction of monocyte/macrophage tissue factor (TF) activity may attenuate the thrombotic risk associated with mechanical…”
Get full text

Marker of erosive progression in RA by SLOT, OLE, BRÜNNER, NILS, STEPHENS, ROSS W

“…[...]another possible bias, tending to increase the difference in suPAR between the two groups in this study, is that patients with high clinical activity…”
Get full text

Heparin binding to the urokinase kringle domain by Stephens, Ross W, Bokman, Anne M, Myohanen, Heli T, Reisberg, Tuuli, Tapiovaara, Hannele, Pedersen, Nina, Groendahl-Hansen, Jan, Llinas, Miguel, Vaheri, Antti

“…The binding of urokinase to immobilized heparin and dextran sulfate was studied using activity assays of the bound urokinase. The markedly higher binding…”
Get full text